AMI Investment Management Inc. Sells 2,725 Shares of Johnson & Johnson (JNJ)  Paula Ricardo | Aug 17th, 2018
AMI Investment Management Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 8.4% in the first quarter, Holdings Channel reports. The institutional investor owned 29,769 shares of the company's stock after selling 2,725 shares during the quarter. Johnson & Johnson comprises 2.4% of AMI Investment Management Inc.'s holdings, making the stock its 14th largest position. AMI Investment Management Inc.'s holdings in Johnson & Johnson were worth $3,815,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in JNJ. BlackRock Inc. lifted its position in Johnson & Johnson by 4.7% in the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company's stock worth $22,476,102,000 after buying an additional 7,853,141 shares during the last quarter. Boston Partners lifted its position in Johnson & Johnson by 68.7% in the first quarter. Boston Partners now owns 12,783,909 shares of the company's stock valued at $1,638,258,000 after purchasing an additional 5,207,124 shares during the last quarter. Mackenzie Financial Corp lifted its position in Johnson & Johnson by 55.1% in the fourth quarter. Mackenzie Financial Corp now owns 4,243,594 shares of the company's stock valued at $592,915,000 after purchasing an additional 1,507,278 shares during the last quarter. Flossbach Von Storch AG lifted its position in Johnson & Johnson by 100.1% in the first quarter. Flossbach Von Storch AG now owns 2,318,450 shares of the company's stock valued at $297,109,000 after purchasing an additional 1,159,690 shares during the last quarter. Finally, Mackay Shields LLC bought a new stake in Johnson & Johnson in the first quarter valued at approximately $110,301,000. Institutional investors own 66.20% of the company's stock. Get Johnson & Johnson alerts:
JNJ opened at $132.48 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a market cap of $350.79 billion, a PE ratio of 17.98, a price-to-earnings-growth ratio of 1.99 and a beta of 0.73.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.06 by $0.04. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The firm had revenue of $20.83 billion for the quarter, compared to analysts' expectations of $20.39 billion. During the same period in the previous year, the firm earned $1.83 earnings per share. The business's revenue was up 10.6% compared to the same quarter last year. equities analysts anticipate that Johnson & Johnson will post 8.14 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th will be paid a dividend of $0.90 per share. The ex-dividend date is Monday, August 27th. This represents a $3.60 annualized dividend and a dividend yield of 2.72%. Johnson & Johnson's dividend payout ratio (DPR) is presently 49.32%.
Several analysts have weighed in on the company. ValuEngine upgraded Johnson & Johnson from a "sell" rating to a "hold" rating in a research report on Saturday, July 28th. Credit Suisse Group lowered their price objective on Johnson & Johnson from $154.00 to $151.00 and set an "outperform" rating for the company in a research report on Friday, April 20th. Citigroup lowered their price objective on Johnson & Johnson from $146.00 to $134.00 and set a "neutral" rating for the company in a research report on Monday, April 23rd. Goldman Sachs Group upgraded Johnson & Johnson from a "sell" rating to a "neutral" rating in a research report on Thursday, July 12th. Finally, Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the company a "buy" rating in a research report on Sunday, July 15th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company. The company has an average rating of "Hold" and a consensus price target of $142.34.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Trading Strategy Methods and Types
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ). Johnson & Johnson Johnson & Johnso